• Fri, September 9, 2022
Matthew Harrison Downgraded (ADCT) to Hold and Decreased Target to $11 on, Sep 9th, 2022
Matthew Harrison of Morgan Stanley, Downgraded "ADC Therapeutics SA" (ADCT) to Hold and Decreased Target from $17 to $11 on, Sep 9th, 2022.
Matthew has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Monday, August 22nd, 2022
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $29 on, Wednesday, August 10th, 2022
Like: 👍
